American College of Gastroenterology Guidelines: Management of Acute Pancreatitis

Abstract

Acute pancreatitis (AP), defined as acute inflammation of the pancreas, is one of the most common diseases of the gastrointestinal tract leading to hospital admission in the United States. It is important for clinicians to appreciate that AP is heterogenous, progressing differently among patients and is often unpredictable. While most patients experience symptoms lasting a few days, almost one-fifth of patients will go on to experience complications, including pancreatic necrosis and/or organ failure, at times requiring prolonged hospitalization, intensive care, and radiologic, surgical, and/or endoscopic intervention. Early management is essential to identify and treat patients with AP to prevent complications. Patients with biliary pancreatitis typically will require surgery to prevent recurrent disease and may need early endoscopic retrograde cholangiopancreatography if the disease is complicated by cholangitis. Nutrition plays an important role in treating patients with AP. The safety of early refeeding and importance in preventing complications from AP are addressed. This guideline will provide an evidence-based practical approach to the management of patients with AP.

Acute Pancreatitis With Normal Amylase and Lipase: A Diagnostic Dilemma

“…Although rare, acute pancreatitis can present with normal pancreatic enzymes, and according to the American College of Gastroenterology, the diagnosis of acute pancreatitis can be made when two out of the following three criteria are met: (1) characteristic abdominal pain, (2) serum amylase and/or lipase more than threefold the upper limit of normal, and (3) CT scan findings compatible with acute pancreatitis [ 8 ].…”

Editorial: Immune dysfunction in acute pancreatitis: from bench to bedside research

“…Acute pancreatitis is an common inflammatory gastrointestinal disease requiring acute admission to hospital ( 1 ). Most patients with acute pancreatitis have mild and self-limited symptoms, while up to 20% of patients develop severe disease requiring intensive care monitoring and support for organ failure ( 2 ).The incidence of AP is increasing at a rate of 2%-5% per year and varies between 3.4 and 73.4 cases per 100,000 worldwide ( 3 ). Despite the global burden of disease, there are currently no effective therapeutic agents to treat or prevent acute pancreatitis ( 4 ).…”